2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

11:30AM-1:30PM: Abstract Number: PP03

Bridging the Gap: Leveraging Social Media to Improve Patient Support; Build a Path to Collaborative Medicine

Patient Perspectives Poster Session

11:30AM-1:30PM: Abstract Number: PP07

Coming to Terms with Lupus: How Learning to Listen to My Body and Letting it Tell Me What to Do Improved My Quality of Life

Patient Perspectives Poster Session

11:30AM-1:30PM: Abstract Number: PP08

Framework for Enhancing Patient-Physician Communication in the Context of Rare Disease

Patient Perspectives Poster Session

11:30AM-1:30PM: Abstract Number: PP01

From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving

Patient Perspectives Poster Session

11:30AM-1:30PM: Abstract Number: PP09

Journeying Towards Hope: Making a Difference in The Lives of Lupus Patients in Mauritius

Patient Perspectives Poster Session

11:30AM-1:30PM: Abstract Number: PP02

Living and Adjusting to a Diagnosis of Rheumatoid Arthritis (RA) with an Interdisciplinary Team

Patient Perspectives Poster Session

11:30AM-1:30PM: Abstract Number: PP05

Race for Relapsing Polychondritis Drives Awareness, Accelerates Research, and Improves the Quality of My Life: How Motorsports Help Me Overcome the Hopelessness of an Incurable, Rare Disease

Patient Perspectives Poster Session

11:30AM-1:30PM: Abstract Number: PP04

Reclaiming Medical Autonomy Through Healthcare Advocacy

Patient Perspectives Poster Session

11:30AM-1:30PM: Abstract Number: PP10

The Practice of Reiki and Meditation in Maintaining Medical Compliance and Decreased Anxiety in an Adult with Juvenile Rheumatoid Arthritis

Patient Perspectives Poster Session

2:30PM-4:00PM: Abstract Number: 876

“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study

3S092: New Approaches to Old Diseases (875–879)

2:30PM-4:00PM: Abstract Number: 828

A Path Model Analysis of the Cognitive Determinants of Physical Activity Among Patients with Fibromyalgia (FM)

3S075: Fibromyalgia & Other Clinical Pain Syndromes (827–832)

2:30PM-4:00PM: Abstract Number: 827

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

3S075: Fibromyalgia & Other Clinical Pain Syndromes (827–832)

2:30PM-4:00PM: Abstract Number: 858

Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE

3S081: SLE – Clinical I: Clinical Trials (857–862)

2:30PM-4:00PM: Abstract Number: 871

ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry

3S085: Vasculitis – ANCA-Associated I (869–874)

2:30PM-4:00PM: Abstract Number: 838

Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?

3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].